SOLAR1s: alpelisib returns to earth?
- PMID: 33309744
- DOI: 10.1016/j.annonc.2020.12.003
SOLAR1s: alpelisib returns to earth?
Conflict of interest statement
Disclosure TF has received institutional grants from Roche and Pfizer and personal fees from Novartis, Pfizer, and UpToDate. AM has declared no conflicts of interest.
Comment on
-
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.Ann Oncol. 2021 Feb;32(2):208-217. doi: 10.1016/j.annonc.2020.11.011. Epub 2020 Nov 25. Ann Oncol. 2021. PMID: 33246021 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous